In clinical trials
Digestive & weight
Larazotide acetate
Evidence
Clinical trials
Class
Tight-junction regulator peptide
KEY TAKEAWAY
Larazotide acetate is an eight-amino-acid peptide designed to keep the gaps between cells of the intestinal lining closed. It was developed for celiac disease. Larazotide is not FDA-approved. A phase 3 trial in celiac disease was stopped in 2022 after an interim review suggested it was unlikely to meet its goal.
Written by the Veylo editorial team · Updated
November 2026
What it is
Tight-junction regulator peptide
Being studied for
Studied as an add-on to a gluten-free diet in celiac disease
Key fact
Larazotide is not FDA-approved. A phase 3 trial in celiac disease was stopped in 2022 after an interim review suggested it was unlikely to meet its goal.
Route
Oral capsule taken before meals in trials
Evidence strength
Clinical trials
Larazotide acetate is an eight-amino-acid peptide designed to keep the gaps between cells of the intestinal lining closed. It was developed for celiac disease.
It is thought to block zonulin signaling, which loosens those cell-to-cell seals, so that fewer gluten fragments cross the gut wall.
Larazotide is not FDA-approved. A phase 3 trial in celiac disease was stopped in 2022 after an interim review suggested it was unlikely to meet its goal.
Studied as an add-on to a gluten-free diet in celiac disease.
Reported side effects in trials were similar to placebo, but a clear benefit was not shown.
Larazotide acetate: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.